Exelixis: A Sunny Future

For Exelixis (EXEL) the two approved oncology products cabozantinib and cobimetinib and its pipeline of promising investigational products are considered now by more analysts a wealth that will be reflected in the firm’s future growth. The results emanating from the clinical trials of two approved products should not be underestimated.

The latest of the good news emanated from the firm’s ongoing Phase 2 clinical trials of Cabometyx™ (cabozantinib) in untreated advanced renal cell carcinoma (RCC). The results demonstrate that Cabo . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.